New perspectives in lung cancer. 2. Growth factors and lung cancer.

Por Woll, P J
Publicado em 1991

Growth factors, antagonists and lung cancer.

Por Woll, P J
Publicado em 1993

Cytokine Therapy

Por Woll, P.J.
Publicado em 1993

Neuropeptide growth factors and cancer.

Por Woll, P. J.
Publicado em 1991

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro.

Por Woll, P J, Rozengurt, E
Publicado em 1988

Bombesin and bombesin antagonists: studies in Swiss 3T3 cells and human small cell lung cancer.

Por Woll, P. J., Rozengurt, E.
Publicado em 1988

Persistent back pain due to malignant lymphadenopathy.

Por Woll, P J, Rankin, E M
Publicado em 1987

Totally implantable vascular access for long term chemotherapy.

Por Woll, P J, Rubens, R D
Publicado em 1986

Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1β and hypoxia in small cell lung cancer

Por Zhu, Y M, Bagstaff, S M, Woll, P J
Publicado em 2006

Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer

Por Coulson, J M, Stanley, J, Woll, P J
Publicado em 1999

Pericardial effusion complicating breast cancer.

Por Woll, P J, Knight, R K, Rubens, R D
Publicado em 1987

Interleukin-8/CXCL8 is a growth factor for human lung cancer cells

Por Zhu, Y M, Webster, S J, Flower, D, Woll, P J
Publicado em 2004

E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer.

Por Coulson, J M, Fiskerstrand, C E, Woll, P J, Quinn, J P
Publicado em 1999

Follow up after Primary Treatment of Soft Tissue Sarcoma: A Survey of Current Practice in the United Kingdom

Por Gerrand, C. H., Billingham, L. J., Woll, P. J., Grimer, R. J.
Publicado em 2007

Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Por Coleman, R. E., Woll, P. J., Miles, M., Scrivener, W., Rubens, R. D.
Publicado em 1988

The roles of HOXD10 in the development and progression of head and neck squamous cell carcinoma (HNSCC)

Por Hakami, F, Darda, L, Stafford, P, Woll, P, Lambert, D W, Hunter, K D
Publicado em 2014

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide

Por Young, R J, Tin, A W, Brown, N J, Jitlal, M, Lee, S M, Woll, P J
Publicado em 2012

The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies – a European survey

Por Lebret, T., Casas, A., Cavo, M., Woll, P.J., Deleplace, C., Kennedy, C., Schoen, P., Jackisch, C.
Publicado no Eur J Cancer Care (Engl) (2016)

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

Por Woll, P. J., Crowther, D., Johnson, P. W., Soukop, M., Harper, P. G., Harris, M., Brampton, M. H., Newlands, E. S.
Publicado em 1995

Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.

Por Woll, P. J., Basser, R., Le Chevalier, T., Drings, P., Perez Manga, G., Adenis, A., Seymour, L., Smith, F., Thatcher, N.
Publicado em 1997